Revelation Partners Taps Prashant Gangwal as CFO

Revelation Partners, the healthcare-focused private equity secondaries manager, has appointed Prashant Gangwal as Partner and Chief Financial Officer, the firm announced Monday. The hire comes seven months after Revelation closed its third fund at $2.4 billion — the largest healthcare-dedicated secondaries vehicle on record — and signals the New York-based firm's intent to build institutional-grade infrastructure as it scales.

Gangwal joins from Coller Capital, where he spent nearly a decade as CFO for the firm's North American operations. Before that, he held senior finance roles at Goldman Sachs and KPMG. He'll oversee Revelation's financial operations, tax, treasury, and fund administration functions — areas that become exponentially more complex as secondaries managers juggle multi-vintage portfolios with staggered capital calls and unpredictable liquidity events.

The appointment isn't just about managing a bigger checkbook. Revelation is moving into a different operational weight class. Managing $2.4 billion across dozens of underlying GP stakes and direct secondaries positions requires a finance function that can handle real-time portfolio valuations, navigate regulatory scrutiny, and satisfy LP reporting demands that have grown dramatically more granular in the post-ILPA Principles 3.0 era.

"Prashant's appointment strengthens our ability to deliver institutional-grade operations at a moment when our LPs are asking harder questions about everything from cash flow forecasting to ESG data tracking," said Thomas Sternberg, Founding Partner of Revelation Partners. "We're not just writing bigger checks — we're running a more complex organism."

Revelation's growth trajectory mirrors a broader shift in the secondaries market, where healthcare has emerged as the most actively traded vertical. According to data from Jefferies, healthcare secondaries transaction volume hit $18.3 billion in 2024, up 41% from the prior year and representing roughly 22% of total secondaries market activity.

The surge isn't random. Healthcare's unique return profile — longer hold periods, regulatory complexity, and binary outcome risk — makes it particularly well-suited for secondaries strategies. LPs who need liquidity from older vintage funds are increasingly willing to accept discounts on healthcare positions, while buyers like Revelation can acquire stakes in proven assets at valuations that reflect near-term uncertainty but ignore long-term fundamentals.

Revelation operates at the intersection of two secondaries subcategories: GP-led restructurings and LP portfolio sales. The firm acquires stakes in single-asset continuation vehicles (where a GP rolls a prized healthcare asset into a new fund structure) and buys LP positions in healthcare-focused funds outright. Both strategies require deep healthcare domain expertise to underwrite assets that might not exit for another 3-5 years.

That domain expertise matters more in healthcare than almost any other sector. A medtech device company facing FDA delays isn't just a growth story that's running late — it's a binary event where the entire investment thesis could evaporate. Revelation's team, which includes former operators from healthcare services and life sciences companies, underwrites these risks differently than generalist secondaries buyers.

Gangwal's move from Coller to Revelation is part of a broader pattern in secondaries talent migration. Coller, founded in 1990, is the largest and oldest dedicated secondaries firm globally, managing over $30 billion. It's become the de facto training ground for secondaries CFOs and COOs who later join specialist managers targeting specific sectors or geographies.

The Coller playbook — rigorous fund administration, conservative valuation methodologies, and a finance team that treats LP reporting as a competitive advantage — is now being exported across the secondaries ecosystem. Gangwal brings that institutional muscle memory to Revelation at a moment when the firm needs it most.

His tenure at Coller overlapped with a period of explosive growth in secondaries deal complexity. When Gangwal joined Coller's North America team in the mid-2010s, the average secondaries transaction was an LP selling a fund interest to generate liquidity. By the time he left, GP-led deals — which require pricing individual assets, negotiating with multiple stakeholders, and managing post-close disputes — had become the dominant transaction type.

Revelation's Fund III will test whether Gangwal's experience managing complexity at scale translates to a smaller, more specialized platform. The firm's LPs include public pension funds, endowments, and family offices — all of which now demand quarterly cash flow projections, scenario-based return modeling, and granular exposure reports broken down by subsector (healthcare services vs. biopharma vs. medtech) and deal type (continuation vehicle vs. LP secondary).

Revelation's hiring spree — Gangwal is the second senior hire announced in the past six months — reflects a structural shift in how secondaries firms compete. The market has bifurcated into two camps: megafunds like Ardian and Lexington Partners that can write $500 million+ checks on any deal, and specialist managers like Revelation that dominate a particular vertical.

The specialist model works when the vertical is large enough to support dedicated capital deployment and opaque enough that domain expertise creates a sustainable edge. Healthcare clears both bars. With over $200 billion in healthcare private equity dry powder globally and hold periods stretching past seven years in many cases, the supply of secondaries opportunities isn't drying up anytime soon.

But the competitive dynamics are shifting. As more capital flows into healthcare secondaries, pricing discipline erodes. Revelation's average purchase price discount to NAV — the key metric that determines future returns — has likely compressed as the firm competes against generalist megafunds that can afford to pay closer to par on attractive assets.

Note: Discount ranges are market estimates based on publicly disclosed transaction data and industry surveys. Actual pricing varies significantly by asset quality, vintage, and seller motivation. *Revelation's range reflects healthcare-specific pricing dynamics where longer hold periods and regulatory risk typically command wider discounts.

For Revelation's limited partners, Gangwal's appointment addresses a practical concern: cash flow predictability. Healthcare secondaries generate distributions on an unpredictable schedule because exit timing depends on factors (FDA approvals, reimbursement policy changes, buyer appetite from strategics) that no GP can control.

Gangwal's immediate priorities likely include upgrading Revelation's fund administration systems, building out a dedicated treasury function, and preparing the firm for its inevitable Fund IV fundraise — which, if market trends hold, could target $3-4 billion.

The treasury function will be critical. Secondaries funds face a liquidity management challenge that traditional buyout funds don't: capital calls and distributions happen on schedules determined by dozens of underlying GPs, not by Revelation's own deal calendar. If five portfolio companies exit in the same quarter, Revelation needs to distribute that capital quickly. If three continuation vehicles call capital simultaneously, the firm needs to ensure LPs can meet those commitments without scrambling.

Fund administration is equally complex. Revelation's Fund III likely holds positions in 30-50 underlying assets across 15-20 different fund structures. Each of those assets gets valued quarterly using different methodologies (public comps for late-stage medtech, DCF for healthcare services roll-ups, precedent transactions for biopharma). Aggregating those valuations into a single NAV figure that satisfies both GAAP accounting standards and LP reporting expectations requires sophisticated systems.

Gangwal's background in building these systems at Coller — where the firm manages over 1,000 underlying fund interests at any given time — positions him to implement best-in-class infrastructure before Revelation's complexity overwhelms its existing tools.

The timing matters. Most secondaries firms wait until after a major operational failure (an LP reporting error, a missed capital call, a valuation dispute) to invest in finance infrastructure. Revelation is betting that hiring Gangwal now, while Fund III is still in its deployment phase, prevents those failures from happening in the first place.

Reading between the lines, Gangwal's appointment suggests Revelation is preparing for a step-function increase in operational complexity over the next 24 months. The firm is likely planning to: (1) increase deal count significantly as Fund III deploys, (2) move upmarket into larger, more complex GP-led transactions, and (3) begin pre-marketing Fund IV to existing LPs.

All three of those moves require a CFO who can scale systems before demand outstrips capacity. Gangwal's track record at Coller suggests he's done exactly that before.

The real test for Revelation — and for Gangwal's finance function — will be whether the firm can maintain pricing discipline as competition intensifies. Healthcare secondaries pricing compressed dramatically in 2024 as generalist megafunds piled into the space, attracted by the same fundamentals that drew Revelation to the market in the first place.

When Revelation closed Fund I in 2018, the firm could routinely buy LP interests in healthcare funds at 25-30% discounts to NAV. By 2024, those discounts had compressed to 15-20% on average, according to data from Evercore's secondaries advisory group. On the most competitive deals — continuation vehicles featuring proven healthcare assets with clear paths to exit — discounts have shrunk to single digits.

That compression matters because it directly impacts returns. A secondaries fund that buys assets at a 25% discount to NAV can generate a 1.5x net multiple even if the underlying assets only appreciate modestly. At a 10% discount, the fund needs significant underlying appreciation just to hit a 1.3x net return.

Revelation's edge — and the reason the firm can still compete against larger rivals — is healthcare expertise. The firm's investment team can underwrite assets that generalist secondaries buyers struggle to price: a behavioral health roll-up with 40 clinics across eight states, a medical device company waiting for FDA clearance on a next-generation product, a specialty pharmacy navigating reimbursement policy changes.

Gangwal's appointment lands at an inflection point for the secondaries market broadly. The industry is experiencing its first sustained period of institutional scrutiny since the 2008 financial crisis, driven by three converging forces: LP liquidity needs, regulatory pressure on fund structures, and a broader reckoning about private equity fee transparency.

LPs are selling positions not because they've lost faith in private equity, but because they're overallocated after a decade of strong returns and minimal distributions. Public pension funds that targeted 10% private equity allocations now find themselves at 13-15% as public market valuations lagged private market marks. Those LPs need to sell something to rebalance, and healthcare positions — with their longer hold periods and binary risk profiles — are often first on the block.

Source: Jefferies Secondaries Advisory, PitchBook. *2024 hold period data reflects deals completed through Q3 2024; full-year data may vary.

Regulatory pressure is intensifying too. The SEC's proposed rules on private fund advisers — which include new restrictions on fee arrangements and heightened reporting requirements — will make secondaries transactions more expensive to execute and harder to structure creatively. Revelation needs a CFO who can navigate that environment without letting compliance costs eat into returns.

Revelation's focus on healthcare isn't just sector specialization — it's a structural bet that domain expertise will remain more valuable than balance sheet size in a market where deals are getting harder to underwrite. The firm's investment team includes former CEOs of healthcare services companies, ex-FDA officials who understand regulatory timelines, and operators who've built and sold medical device businesses.

That expertise shows up in deal selection. Revelation can move quickly on continuation vehicles that involve assets other buyers struggle to value. When a healthcare-focused GP wants to roll a home health platform into a new fund structure, Revelation can underwrite that deal in weeks because the team has pattern recognition around revenue quality, payor mix, and regulatory risk that generalist secondaries buyers lack.

The vulnerability for competitors — particularly generalist megafunds — is that they're underwriting healthcare assets using frameworks built for software and industrials. That works fine when buying stakes in mature, cash-flowing businesses. It breaks down when the asset is pre-revenue, dependent on regulatory approval, or exposed to reimbursement policy risk.

Revelation's returns will ultimately reveal whether that edge is sustainable or whether scale advantages from megafunds — lower cost of capital, faster execution, broader LP relationships — overwhelm sector expertise.

Several questions remain about what Gangwal's hire signals for Revelation's trajectory. First: is the firm preparing to expand beyond healthcare secondaries into adjacent strategies? Some specialist secondaries managers have used their sector expertise to launch co-investment vehicles or direct buyout funds. Gangwal's hire — which strengthens infrastructure but doesn't directly add investment capacity — could be laying groundwork for that expansion.

Second: how will Revelation navigate the inevitable down cycle in healthcare private equity valuations? The sector has enjoyed a sustained run of multiple expansion, particularly in healthcare services and provider-facing businesses. When that reverses — and it will — secondaries pricing will compress even further as LPs become more desperate for liquidity and buyers can afford to be patient.

Third: what's the long-term plan for the firm itself? Revelation is founder-led and institutionally backed, but it hasn't raised a permanent capital vehicle or taken outside capital at the GP level. At some point, the founding partners will need to address succession planning and potentially liquidity for themselves. Gangwal's appointment suggests the firm is building toward something larger than a three-fund platform.

None of those questions will be answered in a press release. But they're the ones LPs are asking behind closed doors as they evaluate whether to commit to Fund IV when Revelation comes back to market — likely sometime in 2026 or 2027.